Oct 5, 2020
Craig Fraser, CEO and President, Windtree Therapeutics talks about acute heart failure, the number one reason for hospitalization in people over 65 and the fact that there has been little innovation in trying to improve cardiac function. Developing a novel dual action drug called istaroxime, Windtree is addressing both...
Oct 5, 2020
Craig Fraser, CEO and President, Windtree Therapeutics talks about acute heart failure, the number one reason for hospitalization in people over 65 and the fact that there has been little innovation in trying to improve cardiac function. Developing a novel dual action drug called istaroxime, Windtree is addressing both...
Sep 23, 2020
Fred Colen, Chief Executive Officer, Neovasc sheds light on the four classes of angina and how the quality of life deteriorates for patients suffering from symptoms. Looking for the fundamental reason for the chronic condition of refractory angina has led Neovasc to address the small blood vessels inside the myocardium,...
Sep 23, 2020
Fred Colen, Chief Executive Officer, Neovasc sheds light on the four classes of angina and how the quality of life deteriorates for patients suffering from symptoms. Looking for the fundamental reason for the chronic condition of refractory angina has led Neovasc to address the small blood vessels inside the myocardium,...
Aug 26, 2020
David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon...